Combined trastuzumab (HER)/docetaxel (TAX) versus sequential trastuzumab followed by docetaxel at progression as first line chemotherapy for Her2-positive metastatic breast cancer: preliminary results (multicenter BOOG-study; 2002-02)
BREAST CANCER RESEARCH AND TREATMENT（2007）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined